Cardio-oncology: chances and challenges

go back to reference Abramov D, Kobo O, Mamas MA (2024) Association of Cardiovascular Health Metrics and Mortality Among Individuals With and Without Cancer. J Am Heart Assoc 13:e032683. https://doi.org/10.1161/JAHA.123.032683CrossRefPubMedPubMedCentral Abramov D, Kobo O, Mamas MA (2024) Association of Cardiovascular Health Metrics and Mortality Among Individuals With and Without Cancer. J Am Heart Assoc 13:e032683. https://​doi.​org/​10.​1161/​JAHA.​123.​032683CrossRefPubMedPubMedCentral

go back to reference Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, Senthivel N, Asavisanu K, Obeid M, Tripodaki ES, Angelis V, Fleming E, Goode EF, John S, Rosen SD, Allen M, Stanway S, Lyon AR, Ring A (2021) Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res 188:149–163. https://doi.org/10.1007/s10549-021-06192-wCrossRef Battisti NML, Andres MS, Lee KA, Ramalingam S, Nash T, Mappouridou S, Senthivel N, Asavisanu K, Obeid M, Tripodaki ES, Angelis V, Fleming E, Goode EF, John S, Rosen SD, Allen M, Stanway S, Lyon AR, Ring A (2021) Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Res 188:149–163. https://​doi.​org/​10.​1007/​s10549-021-06192-wCrossRef

go back to reference Buehning F, Lerchner T, Vogel J et al (2024) Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol 119:1–15. https://doi.org/10.1007/s00395-024-01070-0CrossRef Buehning F, Lerchner T, Vogel J et al (2024) Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy. Basic Res Cardiol 119:1–15. https://​doi.​org/​10.​1007/​s00395-024-01070-0CrossRef

go back to reference Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C, Lamendola P, Tinti L, Teofili L, Hohaus S, Lanza GA, Ferdinandy P, Varga Z, Crea F, Lombardo A, Minotti G (2024) Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01059-9CrossRefPubMed Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C, Lamendola P, Tinti L, Teofili L, Hohaus S, Lanza GA, Ferdinandy P, Varga Z, Crea F, Lombardo A, Minotti G (2024) Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Res Cardiol. https://​doi.​org/​10.​1007/​s00395-024-01059-9CrossRefPubMed

go back to reference Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P, Rodríguez IR, Gómez Prieto P, Buño Soto A, Canales Albendea M, Albaladejo A, Mediavilla G, Feliu Batlle J, Rodríguez Fraga O, Martínez Monzonis A, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, González-Juanatey JR, López-Sendón J, CARDIOTOX registry investigators (2022) Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol 29:859–868. https://doi.org/10.1093/eurjpc/zwaa034CrossRefPubMed Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P, Rodríguez IR, Gómez Prieto P, Buño Soto A, Canales Albendea M, Albaladejo A, Mediavilla G, Feliu Batlle J, Rodríguez Fraga O, Martínez Monzonis A, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, González-Juanatey JR, López-Sendón J, CARDIOTOX registry investigators (2022) Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry. Eur J Prev Cardiol 29:859–868. https://​doi.​org/​10.​1093/​eurjpc/​zwaa034CrossRefPubMed

go back to reference Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, Lang NN, Oudit GY, Touyz RM, American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on the Kidney in Cardiovascular Disease (2023) Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 80:e46–e57. https://doi.org/10.1161/HYP.0000000000000224CrossRefPubMed Cohen JB, Brown NJ, Brown SA, Dent S, van Dorst DCH, Herrmann SM, Lang NN, Oudit GY, Touyz RM, American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on the Kidney in Cardiovascular Disease (2023) Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association. Hypertension 80:e46–e57. https://​doi.​org/​10.​1161/​HYP.​0000000000000224​CrossRefPubMed

go back to reference Cronin M, Crowley A, Davey MG, Ryan P, Abdelshafy M, Elkoumy A, Elzomor H, Arsang-Jang S, Ganly S, Nash P, Crowley J, Sharif F, Simpkin A, Lowery A, Wijns W, Kerin M, Soliman O (2023) Heart failure association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer. J Clin Med 12:1278. https://doi.org/10.3390/jcm12041278CrossRefPubMedPubMedCentral Cronin M, Crowley A, Davey MG, Ryan P, Abdelshafy M, Elkoumy A, Elzomor H, Arsang-Jang S, Ganly S, Nash P, Crowley J, Sharif F, Simpkin A, Lowery A, Wijns W, Kerin M, Soliman O (2023) Heart failure association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer. J Clin Med 12:1278. https://​doi.​org/​10.​3390/​jcm12041278CrossRefPubMedPubMedCentral

go back to reference de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ (2019) Cancer and heart disease: associations and relations. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1539CrossRefPubMed de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ (2019) Cancer and heart disease: associations and relations. Eur J Heart Fail. https://​doi.​org/​10.​1002/​ejhf.​1539CrossRefPubMed

go back to reference Efentakis P, Choustoulaki A, Kwiatkowski G et al (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol 119:1–12. https://doi.org/10.1007/s00395-024-01046-0CrossRef Efentakis P, Choustoulaki A, Kwiatkowski G et al (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol 119:1–12. https://​doi.​org/​10.​1007/​s00395-024-01046-0CrossRef

go back to reference Fuster JJ (2021) Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thromb Res 206:143–151. https://doi.org/10.1016/j.thromres.2021.12.009CrossRef Fuster JJ (2021) Clonal hematopoiesis and cardiovascular disease in cancer patients and survivors. Thromb Res 206:143–151. https://​doi.​org/​10.​1016/​j.​thromres.​2021.​12.​009CrossRef

go back to reference Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Agüero J, Fernández-Jiménez R, Martín-García A, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez PL, Fuster V, Sánchez-González J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779–791. https://doi.org/10.1016/j.jacc.2018.11.046CrossRefPubMed Galán-Arriola C, Lobo M, Vílchez-Tschischke JP, López GJ, de Molina-Iracheta A, Pérez-Martínez C, Agüero J, Fernández-Jiménez R, Martín-García A, Oliver E, Villena-Gutierrez R, Pizarro G, Sánchez PL, Fuster V, Sánchez-González J, Ibanez B (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779–791. https://​doi.​org/​10.​1016/​j.​jacc.​2018.​11.​046CrossRefPubMed

go back to reference Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, Molina-Iracheta A, Pérez-Martínez C, García RD, González-Calle D, Lobo M, Sánchez PL, Oliver E, Córdoba R, Fuster V, Sánchez-González J, Ibanez B (2021) Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res 117:1132–1143. https://doi.org/10.1093/cvr/cvaa181CrossRefPubMed Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, Díaz-Rengifo IA, Pizarro G, López GJ, Molina-Iracheta A, Pérez-Martínez C, García RD, González-Calle D, Lobo M, Sánchez PL, Oliver E, Córdoba R, Fuster V, Sánchez-González J, Ibanez B (2021) Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res 117:1132–1143. https://​doi.​org/​10.​1093/​cvr/​cvaa181CrossRefPubMed

go back to reference Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV (2024) Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01068-8CrossRefPubMed Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV (2024) Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. https://​doi.​org/​10.​1007/​s00395-024-01068-8CrossRefPubMed

go back to reference Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R (2021) Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 10:947–959. https://doi.org/10.1093/ehjacc/zuab056CrossRefPubMed Gevaert SA, Halvorsen S, Sinnaeve PR, Sambola A, Gulati G, Lancellotti P, Van Der Meer P, Lyon AR, Farmakis D, Lee G, Boriani G, Wechalekar A, Okines A, Asteggiano R (2021) Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care 10:947–959. https://​doi.​org/​10.​1093/​ehjacc/​zuab056CrossRefPubMed

go back to reference Glen C, Adam S, McDowell K, Waterston A, Tan YY, Petrie MC, Coats CJ, Lang NN (2023) Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores. JACC CardioOncol 5:628–637. https://doi.org/10.1016/j.jaccao.2023.04.004CrossRefPubMedPubMedCentral Glen C, Adam S, McDowell K, Waterston A, Tan YY, Petrie MC, Coats CJ, Lang NN (2023) Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores. JACC CardioOncol 5:628–637. https://​doi.​org/​10.​1016/​j.​jaccao.​2023.​04.​004CrossRefPubMedPubMedCentral

go back to reference Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C (2020) Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2:270–292. https://doi.org/10.1016/j.jaccao.2020.04.011CrossRefPubMedPubMedCentral Harries I, Liang K, Williams M, Berlot B, Biglino G, Lancellotti P, Plana JC, Bucciarelli-Ducci C (2020) Magnetic Resonance Imaging to Detect Cardiovascular Effects of Cancer Therapy: JACC CardioOncology State-of-the-Art Review. JACC CardioOncol 2:270–292. https://​doi.​org/​10.​1016/​j.​jaccao.​2020.​04.​011CrossRefPubMedPubMedCentral

go back to reference Heusch G, Rassaf T (2021) Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning? Cardiovasc Res 117:985–986. https://doi.org/10.1093/cvr/cvaa199CrossRefPubMed Heusch G, Rassaf T (2021) Protection from cardiotoxicity of cancer chemotherapy: a novel target for remote ischaemic conditioning? Cardiovasc Res 117:985–986. https://​doi.​org/​10.​1093/​cvr/​cvaa199CrossRefPubMed

go back to reference Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144–e145. https://doi.org/10.1093/cvr/cvad111CrossRefPubMed Heusch G (2023) Cardioprotection in cardio-oncology: a case for concern? Cardiovasc Res 119:e144–e145. https://​doi.​org/​10.​1093/​cvr/​cvad111CrossRefPubMed

go back to reference Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O’Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43:280–299. https://doi.org/10.1093/eurheartj/ehab674CrossRefPubMed Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O’Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43:280–299. https://​doi.​org/​10.​1093/​eurheartj/​ehab674CrossRefPubMed

go back to reference Ibáñez B, Gomes-Silva M (2023) Remote ischemic conditioning for anthracycline cardiotoxicity: the need to protect the most vulnerable. JACC CardioOncol 5:356–359. https://doi.org/10.1016/j.jaccao.2023.05.002CrossRefPubMedPubMedCentral Ibáñez B, Gomes-Silva M (2023) Remote ischemic conditioning for anthracycline cardiotoxicity: the need to protect the most vulnerable. JACC CardioOncol 5:356–359. https://​doi.​org/​10.​1016/​j.​jaccao.​2023.​05.​002CrossRefPubMedPubMedCentral

go back to reference Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40:1756–1763. https://doi.org/10.1093/eurheartj/ehy453CrossRefPubMed Lancellotti P, Suter TM, López-Fernández T, Galderisi M, Lyon AR, Van der Meer P, Cohen Solal A, Zamorano JL, Jerusalem G, Moonen M, Aboyans V, Bax JJ, Asteggiano R (2019) Cardio-Oncology Services: rationale, organization, and implementation. Eur Heart J 40:1756–1763. https://​doi.​org/​10.​1093/​eurheartj/​ehy453CrossRefPubMed

go back to reference Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, Asteggiano R, Szmit S, Cohen-Solal A, Abdin A, Jurczak W, Garrido Lopez P, Sverdlov AL, Tocchetti CG, Barac A, Parrini I, Zamorano P, Iakobishvili Z, Pudil R, Badimon L, Kirby AM, Blaes AH, Farmakis D, Curigliano G, Stephens R, Lyon AR, Lopez-Fernandez T (2022) European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes 9:1–7. https://doi.org/10.1093/ehjqcco/qcac070CrossRefPubMedPubMedCentral Lee GA, Aktaa S, Baker E, Gale CP, Yaseen IF, Gulati G, Asteggiano R, Szmit S, Cohen-Solal A, Abdin A, Jurczak W, Garrido Lopez P, Sverdlov AL, Tocchetti CG, Barac A, Parrini I, Zamorano P, Iakobishvili Z, Pudil R, Badimon L, Kirby AM, Blaes AH, Farmakis D, Curigliano G, Stephens R, Lyon AR, Lopez-Fernandez T (2022) European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. Eur Heart J Qual Care Clin Outcomes 9:1–7. https://​doi.​org/​10.​1093/​ehjqcco/​qcac070CrossRefPubMedPubMedCentral

go back to reference Li W, Wang Z, Jiang C, Hua C, Tang Y, Zhang H, Liu X, Zheng S, Wang Y, Gao M, Lv Q, Dong J, Ma C, Du X (2024) Effect of intensive blood pressure control on cardiovascular outcomes in cancer survivors. Hypertension 81:620–628. https://doi.org/10.1161/HYPERTENSIONAHA.123.22194CrossRefPubMed Li W, Wang Z, Jiang C, Hua C, Tang Y, Zhang H, Liu X, Zheng S, Wang Y, Gao M, Lv Q, Dong J, Ma C, Du X (2024) Effect of intensive blood pressure control on cardiovascular outcomes in cancer survivors. Hypertension 81:620–628. https://​doi.​org/​10.​1161/​HYPERTENSIONAHA.​123.​22194CrossRefPubMed

go back to reference López-Fernández T, Farmakis D, Ameri P, Asteggiano R, de Azambuja E, Aznar M, Barac A, Bayes-Genis A, Bax JJ, Bergler-Klein J, Boriani G, Celutkiene J, Coats A, Cohen-Solal A, Córdoba R, Cosyns B, Filippatos G, Fox K, Gulati G, Inciardi RM, Lee G, Mamas MA, Novo G, Plummer C, Psyrri A, Rakisheva A, Suter T, Tini G, Tocchetti CG, Toutouzas K, Wilhelm M, Metra M, Lyon AR, Rosano GMC (2024) European Society of Cardiology Core Curriculum for cardio-oncology. Eur J Heart Fail 26:754–771. https://doi.org/10.1002/ejhf.3102CrossRefPubMed López-Fernández T, Farmakis D, Ameri P, Asteggiano R, de Azambuja E, Aznar M, Barac A, Bayes-Genis A, Bax JJ, Bergler-Klein J, Boriani G, Celutkiene J, Coats A, Cohen-Solal A, Córdoba R, Cosyns B, Filippatos G, Fox K, Gulati G, Inciardi RM, Lee G, Mamas MA, Novo G, Plummer C, Psyrri A, Rakisheva A, Suter T, Tini G, Tocchetti CG, Toutouzas K, Wilhelm M, Metra M, Lyon AR, Rosano GMC (2024) European Society of Cardiology Core Curriculum for cardio-oncology. Eur J Heart Fail 26:754–771. https://​doi.​org/​10.​1002/​ejhf.​3102CrossRefPubMed

go back to reference Lopez-Mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, Chen MY, Meyersohn N, Daly R, Slim A, Rochitte C, Blaha M, Whelton S, Dzaye O, Dent S, Milgrom S, Ky B, Iliescu C, Mamas MA, Ferencik M (2023) Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Comput Tomogr 17:66–83. https://doi.org/10.1016/j.jcct.2022.09.002CrossRefPubMed Lopez-Mattei J, Yang EH, Baldassarre LA, Agha A, Blankstein R, Choi AD, Chen MY, Meyersohn N, Daly R, Slim A, Rochitte C, Blaha M, Whelton S, Dzaye O, Dent S, Milgrom S, Ky B, Iliescu C, Mamas MA, Ferencik M (2023) Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). J Cardiovasc Comput Tomogr 17:66–83. https://​doi.​org/​10.​1016/​j.​jcct.​2022.​09.​002CrossRefPubMed

go back to reference López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodríguez Rodríguez I, Rodríguez Fraga O, Albaladejo A, Mediavilla G, González-Juanatey JR, Martínez Monzonis A, Gómez Prieto P, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, López FT (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41:1720–1729. https://doi.org/10.1093/eurheartj/ehaa006CrossRefPubMed López-Sendón J, Álvarez-Ortega C, Zamora Auñon P, Buño Soto A, Lyon AR, Farmakis D, Cardinale D, Canales Albendea M, Feliu Batlle J, Rodríguez Rodríguez I, Rodríguez Fraga O, Albaladejo A, Mediavilla G, González-Juanatey JR, Martínez Monzonis A, Gómez Prieto P, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, López FT (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J 41:1720–1729. https://​doi.​org/​10.​1093/​eurheartj/​ehaa006CrossRefPubMed

go back to reference Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22:1945–1960. https://doi.org/10.1002/ejhf.1920CrossRefPubMed Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D (2020) Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22:1945–1960. https://​doi.​org/​10.​1002/​ejhf.​1920CrossRefPubMed

go back to reference Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229–4361. https://doi.org/10.1093/eurheartj/ehac244CrossRefPubMed Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH, ESC Scientific Document Group (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43:4229–4361. https://​doi.​org/​10.​1093/​eurheartj/​ehac244CrossRefPubMed

go back to reference Meijers WC, de Boer RA (2019) Common risk factors for heart failure and cancer. Cardiovasc Res 115:844–853. https://doi.org/10.1093/cvr/cvz035CrossRefPubMedPubMedCentral Meijers WC, de Boer RA (2019) Common risk factors for heart failure and cancer. Cardiovasc Res 115:844–853. https://​doi.​org/​10.​1093/​cvr/​cvz035CrossRefPubMedPubMedCentral

go back to reference Mohamed MO, Van Spall HG, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, Khan SU, Kwok CS, Shoaib A, Bhatt DL, Mamas MA (2021) Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 10:829–839. https://doi.org/10.1093/ehjacc/zuaa032CrossRefPubMed Mohamed MO, Van Spall HG, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, Khan SU, Kwok CS, Shoaib A, Bhatt DL, Mamas MA (2021) Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 10:829–839. https://​doi.​org/​10.​1093/​ehjacc/​zuaa032CrossRefPubMed

go back to reference Porter C, Azam TU, Mohananey D, Kumar R, Chu J, Lenihan D, Dent S, Ganatra S, Beasley GS, Okwuosa T (2022) Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol 4:302–312. https://doi.org/10.1016/j.jaccao.2022.07.005CrossRefPubMedPubMedCentral Porter C, Azam TU, Mohananey D, Kumar R, Chu J, Lenihan D, Dent S, Ganatra S, Beasley GS, Okwuosa T (2022) Permissive cardiotoxicity: the clinical crucible of cardio-oncology. JACC CardioOncol 4:302–312. https://​doi.​org/​10.​1016/​j.​jaccao.​2022.​07.​005CrossRefPubMedPubMedCentral

go back to reference Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Štěrba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hägler-Laube ES, Asteggiano R, Lopez Fernandez T, de Boer RA, Lyon AR (2020) Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22(11):1966–1983. https://doi.org/10.1002/ejhf.2017CrossRefPubMed Pudil R, Mueller C, Čelutkienė J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Štěrba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hägler-Laube ES, Asteggiano R, Lopez Fernandez T, de Boer RA, Lyon AR (2020) Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22(11):1966–1983. https://​doi.​org/​10.​1002/​ejhf.​2017CrossRefPubMed

go back to reference Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Martínez Monzonis A, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodriguez I, Buño Soto A, Cadenas R, Palacios Ozores P, Pérez Ramírez S, Merino Salvador M, Valbuena S, Fernández Gasso L, Juárez V, Severo A, Terol B, de Soto ÁT, Rodríguez O, Brion M, González-Costello J, Canales Albendea M, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T (2024) Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. https://doi.org/10.1093/eurheartj/ehae496CrossRefPubMed Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Martínez Monzonis A, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodriguez I, Buño Soto A, Cadenas R, Palacios Ozores P, Pérez Ramírez S, Merino Salvador M, Valbuena S, Fernández Gasso L, Juárez V, Severo A, Terol B, de Soto ÁT, Rodríguez O, Brion M, González-Costello J, Canales Albendea M, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T (2024) Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. https://​doi.​org/​10.​1093/​eurheartj/​ehae496CrossRefPubMed

go back to reference Sadler D, Okwuosa T, Teske AJ, Guha A, Collier P, Moudgil R, Sarkar A, Brown SA (2022) Cardio oncology: Digital innovations, precision medicine and health equity. Front Cardiovasc Med 9:951551. https://doi.org/10.3389/fcvm.2022.951551CrossRefPubMedPubMedCentral Sadler D, Okwuosa T, Teske AJ, Guha A, Collier P, Moudgil R, Sarkar A, Brown SA (2022) Cardio oncology: Digital innovations, precision medicine and health equity. Front Cardiovasc Med 9:951551. https://​doi.​org/​10.​3389/​fcvm.​2022.​951551CrossRefPubMedPubMedCentral

go back to reference Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, Burridge P, Cabrera JÁ, de Castro J, Córdoba R, Costa A, Dent S, Engelbertsen D, Fernández-Velasco M, Fradley M, Fuster JJ, Galán-Arriola C, García-Lunar I, Ghigo A, González-Neira A, Hirsch E, Ibáñez B, Kitsis RN, Konety S, Lyon AR, Martin P, Mauro AG, Mazo Vega MM, Meijers WC, Neilan TG, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, López-Fernández T, Salloum F, Tocchetti C, Ameri P, Ardehali H, Asnani A, de Boer R, Burridge P, Cabrera J, de Castro J, Córdoba R, Costa A, Dent S, Engelbertsen D, Fernández-Velasco M, Fradley M, Fuster J, Galán-Arriola C, García-Lunar I, Ghigo A, González-Neira A, Hirsch E, Ibáñez B, Kitsis R, Konety S, Lyon A, Martin P, Mauro A, Mazo Vega M, Meijers W, Neilan T, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, López-Fernández T, International Cardio-Oncology Society (2023) Priorities in cardio-oncology basic and translational science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 5:715–731. https://doi.org/10.1016/j.jaccao.2023.08.003CrossRefPubMedPubMedCentral Salloum FN, Tocchetti CG, Ameri P, Ardehali H, Asnani A, de Boer RA, Burridge P, Cabrera JÁ, de Castro J, Córdoba R, Costa A, Dent S, Engelbertsen D, Fernández-Velasco M, Fradley M, Fuster JJ, Galán-Arriola C, García-Lunar I, Ghigo A, González-Neira A, Hirsch E, Ibáñez B, Kitsis RN, Konety S, Lyon AR, Martin P, Mauro AG, Mazo Vega MM, Meijers WC, Neilan TG, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, López-Fernández T, Salloum F, Tocchetti C, Ameri P, Ardehali H, Asnani A, de Boer R, Burridge P, Cabrera J, de Castro J, Córdoba R, Costa A, Dent S, Engelbertsen D, Fernández-Velasco M, Fradley M, Fuster J, Galán-Arriola C, García-Lunar I, Ghigo A, González-Neira A, Hirsch E, Ibáñez B, Kitsis R, Konety S, Lyon A, Martin P, Mauro A, Mazo Vega M, Meijers W, Neilan T, Rassaf T, Ricke-Hoch M, Sepulveda P, Thavendiranathan P, van der Meer P, Fuster V, Ky B, López-Fernández T, International Cardio-Oncology Society (2023) Priorities in cardio-oncology basic and translational science: GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 5:715–731. https://​doi.​org/​10.​1016/​j.​jaccao.​2023.​08.​003CrossRefPubMedPubMedCentral

go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763CrossRefPubMed Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://​doi.​org/​10.​3322/​caac.​21763CrossRefPubMed

go back to reference Suero-Abreu GA, Zanni MV, Neilan TG (2022) Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4:598–615. https://doi.org/10.1016/j.jaccao.2022.11.011CrossRefPubMedPubMedCentral Suero-Abreu GA, Zanni MV, Neilan TG (2022) Atherosclerosis with immune checkpoint inhibitor therapy: evidence, diagnosis, and management: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 4:598–615. https://​doi.​org/​10.​1016/​j.​jaccao.​2022.​11.​011CrossRefPubMedPubMedCentral

go back to reference Suntheralingam S, Fan CS, Calvillo-Argüelles O, Abdel-Qadir H, Amir E, Thavendiranathan P (2022) Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2+ breast cancer. J Clin Med 11:847. https://doi.org/10.3390/jcm11030847CrossRefPubMedPubMedCentral Suntheralingam S, Fan CS, Calvillo-Argüelles O, Abdel-Qadir H, Amir E, Thavendiranathan P (2022) Evaluation of risk prediction models to identify cancer therapeutics related cardiac dysfunction in women with HER2+ breast cancer. J Clin Med 11:847. https://​doi.​org/​10.​3390/​jcm11030847CrossRefPubMedPubMedCentral

go back to reference Teske AJ, Moudgil R, López-Fernández T, Barac A, Brown SA, Deswal A, Neilan TG, Ganatra S, Abdel Qadir H, Menon V, Sverdlov AL, Cheng RK, Makhoul S, Ghosh AK, Szmit S, Zaha V, Addison D, Zhang L, Herrmann J, Chong JH, Agarwala V, Iakobishvili Z, Guerrero P, Yang EH, Leja M, Akhter N, Guha A, Okwuosa TM, Silva CC, Collier P, DeCara J, Bauer B, Lenneman CE, Sadler D (2023) Global Cardio Oncology Registry (G-COR): registry design, primary objectives, and future perspectives of a multicenter global initiative. Circ Cardiovasc Qual Outcomes 16:e009905. https://doi.org/10.1161/CIRCOUTCOMES.123.009905CrossRefPubMed Teske AJ, Moudgil R, López-Fernández T, Barac A, Brown SA, Deswal A, Neilan TG, Ganatra S, Abdel Qadir H, Menon V, Sverdlov AL, Cheng RK, Makhoul S, Ghosh AK, Szmit S, Zaha V, Addison D, Zhang L, Herrmann J, Chong JH, Agarwala V, Iakobishvili Z, Guerrero P, Yang EH, Leja M, Akhter N, Guha A, Okwuosa TM, Silva CC, Collier P, DeCara J, Bauer B, Lenneman CE, Sadler D (2023) Global Cardio Oncology Registry (G-COR): registry design, primary objectives, and future perspectives of a multicenter global initiative. Circ Cardiovasc Qual Outcomes 16:e009905. https://​doi.​org/​10.​1161/​CIRCOUTCOMES.​123.​009905CrossRefPubMed

go back to reference Thuny F, Naidoo J, Neilan TG (2022) Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J 43:4458–4468. https://doi.org/10.1093/eurheartj/ehac456CrossRefPubMedPubMedCentral Thuny F, Naidoo J, Neilan TG (2022) Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J 43:4458–4468. https://​doi.​org/​10.​1093/​eurheartj/​ehac456CrossRefPubMedPubMedCentral

go back to reference Wernhart S, Rassaf T (2024) Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights. Basic Res Cardiol 119:1–13. https://doi.org/10.1007/s00395-024-01034-4CrossRef Wernhart S, Rassaf T (2024) Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights. Basic Res Cardiol 119:1–13. https://​doi.​org/​10.​1007/​s00395-024-01034-4CrossRef

go back to reference Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G (2020) The cancer patient and cardiology. Eur J Heart Fail 22:2290–2309. https://doi.org/10.1002/ejhf.1985CrossRefPubMed Zamorano JL, Gottfridsson C, Asteggiano R, Atar D, Badimon L, Bax JJ, Cardinale D, Cardone A, Feijen EAM, Ferdinandy P, López-Fernández T, Gale CP, Maduro JH, Moslehi J, Omland T, Plana Gomez JC, Scott J, Suter TM, Minotti G (2020) The cancer patient and cardiology. Eur J Heart Fail 22:2290–2309. https://​doi.​org/​10.​1002/​ejhf.​1985CrossRefPubMed